freegamestowincrypto| The concept of stem cells is popular and many listed companies speak out

Stock speculation to see Jin Kirin analyst research report, authoritative, professional, timely, comprehensive, to help you tap the potential of the theme opportunity!

Liu Qian, a reporter from the Securities Times

The concept of stem cells has been hot recently. by the close of trading on May 9, Tailin Biology and Kaileng Health had harvested the 20cm trading limit for two consecutive trading days, while Sihuan Biology, Vcanbio, Nanhua Biology and Nanjing Xinbai had two consecutive trading days. In addition, Guan Hao Bio is up 9.Freegamestowincrypto.22%, Xiangxue Pharmaceutical rose 6.26%.

On the evening of May 9, the relevant listed companies issued a notice of stock price changes. Jimin Medical, which is trading on Sanlianban, said that stem cell drug research and development pipeline projects are in the preclinical stage, and Erlianban Hanshang Group said it does not carry out stem cell treatment business at present.

Jiemin Medical treatment:

The project is in the preclinical stage.

In the stock trading announcement issued on the evening of May 9, Jimin Medical said that the Boao International Hospital under the company's flag (Jin Kirin analyst) signed a cooperation agreement with Professor Jonathan Robert Todd Lakey in January 2019, hiring Professor Jonathan Robert Todd Lakey as the chief scientist, whose main responsibility is to provide technical support to the hospital in stem cell related fields and jointly carry out scientific research projects for a period of three years. Up to now, the cooperation between the two sides has been completed, and the company has not promoted the transformation of its related scientific research achievements in China.

In addition, the current stem cell drug research and development pipeline of Boao International Hospital mainly includes adipose mesenchymal stem cells (ADSC) for retinitis pigmentosa (RP), adipose mesenchymal stem cells (ADSC) for type 2 diabetes mellitus (T2DM), and adipose mesenchymal stem cells (ADSC) for chronic obstructive pulmonary disease (COPD), but they are all in the preclinical stage and the project is relatively early. Innovative drug research and development cycle is long, many links, high risk, from development, clinical trials, application to production is easily affected by technology, examination and approval, policies and many other factors, there are many uncertainties in the follow-up research and development.

Since May 7, Jimin Medical has risen by the daily limit for three consecutive days, with a cumulative increase of 33%, a short-term increase higher than the Shanghai Composite Index for the same period. "there is a situation of overheated market sentiment," the company said.

Han Shang Group:

No stem cell therapy business

On the same day, Hanshang Group said in the stock trading announcement that the company is not currently engaged in stem cell therapy business. Wuhan Huake Reproductive Hospital of the company has been awarded the license of "Hubei Engineering Research Center for preparation and Application of Human Stem cells and Resource Preservation". At present, it is in the early stage of research and development and has not yet carried out clinical application.

At present, Han Shang Group is promoting the dual-main business strategy of "Big Business + Great Health". The Great Health Plate owns Dikang Pharmaceutical, Dikang traditional Chinese Medicine, Wuhan Huake Reproductive Hospital and so on.

From May 8 to 9, the Chinese Merchants Group rose by the daily limit for two consecutive days, with a cumulative increase of 21%.

On the news side, at the performance presentation meeting that ended on May 8, the Han Shang Group revealed that last year, Wuhan Huaxue Reproductive Hospital made 30, 000 visits, completed 1060 transplant cycles, preserved 180 fertility, and stored a total of 5100 specimens in the sperm bank. Through the special qualification verification and evaluation of the concession, AID and IVF frozen embryo and fresh embryo technology have been in the leading level in China, and the human sperm bank and fertility conservation center have achieved their annual business targets ahead of schedule, of which self-polishing fees have increased by 72% compared with the same period last year, a record high.

Han Shang Group acquired 81.34% of the equity of Wuhan Tongji Science and Technology Group Co., Ltd., the investor of Huake Reproductive Hospital in January last year. At present, the company directly and indirectly holds 76% of the capital contribution share of Huake Reproductive Hospital, and the actors in concert with the company have 100% voting rights in the general meeting of investors of Huake Reproductive Hospital. At present, the company is promoting the restructuring of Huake Reproductive Hospital.

In addition, Sihuan Biology, Tailin Biology, Vcanbio, Nanhua Biology, etc., have also issued announcements that the company's operating situation and internal and external business environment have not changed significantly.

Enterprises ahead of the progress of pipeline development

Or have a better chance.

Stem cell medicine (StemCellTherapy) refers to the use of stem cells to treat and repair the function of human tissues and organs. Stem cell medicine is widely used in the treatment and tissue repair of various diseases.

The reporter noticed that a number of A-share companies answered relevant business trends on the investor interaction platform.

Vcanbio said that the company's main business includes cell detection preparation and storage in the field of "precision prevention".FreegamestowincryptoResearch and development of in vitro diagnostic raw materials, in vitro diagnostic reagents and instruments, biological genes, proteins, antibodies and other scientific research reagents in the field of "accurate diagnosis", as well as gene detection services; research and development of clinical applications of stem cells and immune cells in the field of "cell therapy".

Xiangxue Pharmaceutical said that Xiangxue Life Sciences, a subsidiary of Xiangxue Pharmaceutical, is a research and development enterprise focusing on cellular immunotherapy products and technologies in the field of TCR. TCR-T products are widely distributed, multiple research pipelines are promoted at the same time, and the targets are rich, including almost all tumor-related specific antigens, including CT antigens, newborn antigens, virus antigens and so on.

East China Pharmaceutical said that on March 1 this year, the company reached an exclusive commercial cellular immunotherapy product with Keji Pharmaceutical Co., Ltd. Zevoji Orensai injection was notified by the State Drug Administration (NMPA) with conditional approval for listing, and the company has set up a special commercial team, and the first prescription for the product was issued on the day the product was approved for market. At present, the product is actively promoting hospital access and urban access to civil insurance.

According to open source securities, the number of patients with autoimmune diseases in China continues to increase, and there are fewer targeted drugs on the market in China, the permeability of biological agents is low, and there is more unmet demand. It is suggested that attention should be paid to the targets that have been verified overseas but the number of drugs on the domestic market is still relatively small, and the enterprises that are ahead of the pipeline research and development will have greater development opportunities.